AMAT · Investment summary · as of 12 August 2026
Priced for an operating path the record does not support
Business type: Cyclical · cyclical or commodity-sensitive
The operating path required by today's price is not achievable on the evidence.
At $548.15, AMAT requires a 37% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 11%.
The conditions that would settle the disagreement are dated to August 2026.
The value rests on an exit multiple of 15.4x, a terminal operating margin of 29% and a 10.8% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: China export controls plus Chinese domestic-equipment substitution on 30.1% of FY2025 revenue ($8.53bn), compounded by the DRAM share slide (28%->26% of Semiconductor Systems during the memory boom).
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Cyclical / commodity-sensitive: revenue and margin driven by exogenous WFE/fab-utilisation/memory cycle. Through-cycle FY2016-FY2025 operating margin 19.9/27.9/30.2 min/median/max. |
| What do we forecast? | Revenue growth of 11% demonstrated; a terminal operating margin of 29%; an exit multiple of 15.4x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -25.9 percentage points. |
| What is it worth? | Not determined — It is struck at this name's next touch. |
| Why now? | The first dated test of the thesis falls on 13 August 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 13 August 2026 | Next scheduled results | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| 13 August 2026 | ContractWithCustomerLiability | Contract liabilities at or above $2,450m (downward break of the 2-year $2.45-2.85bn band) | Contract liabilities below $2,450m (downward break of the 2-year $2.45-2.85bn band) |
| FY2026 10-K (~Dec 2026) | 10-K geographic note China % | FY2026 China revenue share at or above 25% (vs 30.1% FY2025) | FY2026 China revenue share below 25% (vs 30.1% FY2025) |
| from FQ3'26, two consecutive quarters | Quarterly GAAP gross margin | GAAP gross margin at or above 47% for two consecutive quarters | GAAP gross margin below 47% for two consecutive quarters |
China export controls plus Chinese domestic-equipment substitution on 30.1% of FY2025 revenue ($8.53bn), compounded by the DRAM share slide (28%->26% of Semiconductor Systems during the memory boom). Structural, not cyclical, loss channel. Not going-concern (net cash $1.79bn, IG).
Estimated probability 20%, against the 12% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | China export controls plus Chinese domestic-equipment substitution on 30.1% of FY2025 revenue ($8.53bn), compounded by the DRAM share slide (28%->26% of Semiconductor Systems during the memory boom). |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -25.9 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: china export controls plus Chinese domestic-equipment substitution on 30.1% of FY2025 revenue ($8.53bn), compounded by the DRAM share slide (28%->26% of Semiconductor Systems during the memory boom). The next evidence that should change the portfolio decision is the test dated 13 August 2026, or a daily close below $442.42, which forces an immediate review.